FDA Modernization Act 3.0
This bill directs the Food and Drug Administration (FDA) to update its formal regulations so drug companies can use non-animal testing methods when applying to test and sell new medicines. Federal rules will officially accept scientifically valid alternatives—such as lab-grown human tissues, organ-on-a-chip systems, and computer models—alongside or in place of traditional animal studies. This update aims to cut regulatory confusion, speed up drug development, and reduce the use of animals in pharmaceutical research.
What this bill touches.
Who it helps · who it burdens.
Who it helps
- Drug and biologic developersDrug and biological product developers gain the regulatory clarity and ability to submit broader nonclinical tests, models, and data instead of strictly animal-based studies in their applications and filings (Sec. 2(a)).
Who it burdens
- Food and Drug Administration and Department of Health and Human ServicesThe Secretary of Health and Human Services and the Food and Drug Administration are required within one year to publish and implement an immediately effective interim final rule amending federal regulations to replace references to animal testing with nonclinical testing terms (Sec. 2(a)).
The provisions, in plain language.
Requires the Food and Drug Administration within one year to update federal regulations for drug and biologic reviews by replacing references to animal testing and studies with "nonclinical tests," allowing drug developers to use alternative testing methods like cell cultures and computer models under an immediately effective rule.